CSTL ▼ -0.3% - Castle Biosciences, Inc.
$CSTL CSTL - New Study Highlights Clinical Need for Molecular Guidance in Atopic Dermatitis Treatment Selection, Reinforcing the Value of AdvanceAD-Tx™
24-SEP-2026 04:30 PM ET
Share this post
More filings for $CSTL
View full $CSTL filing history →💬 Comments
Loading comments…
Leave a comment
